Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Of...
2023-03-27 17:13:08 ET Harpoon Therapeutics press release ( NASDAQ: HARP ): Q4 GAAP EPS of -$0.55 misses by $0.08 . Revenue of $4.1M (-5.3% Y/Y) misses by $2.94M . Shares -4.26% AH. For further details see: Harpoon Therapeutics GAAP EPS of -$0.55 ...
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred equity financing provides sufficient cash to fund operations into the second half o...
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred s...
Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC ® ) platform and support ongoing clinical efforts Additional abstrac...
The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this event. For further details see: Harpoon Therapeutics (HARP) Presents at SVB Securities Global Biopharma Conference 2023
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That’s because, with penny stocks, investors’ capital appreciation upside potential is amplified...
FinancialBuzz.com’s latest The Buzz Show: Featuing Our Corporate News Recap on “ Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial” Harpoon Therapeutics, Inc. (NASDAQ: HARP) , a clinical-stag...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Evgeny Karandaev/ShutterStock.com Reborn Coffee (NASDAQ: REBN ) stock is heating up on Monday as investors take note of the California coffee company’s shares. With that comes heavy trading of REB...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NYSE Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...